Viruses and Human Disease, 2nd Edition by James H. Strauss, and Ellen G. Strauss Hardcover - 480 pages Shipped in CLICK HERE Cat.# EL-BVI7 $104.55 BUY Published:  2008   ISBN:  9780123737410

Key Features:

• Includes over 30% new material - virtually all of the figures and tables have been redrawn to include the latest information and the text has been extensively rewritten to include the most up-to-date information
• Includes a new chapter on emerging and reemerging viral diseases such as avian flu, SARS, the spread of West Nile virus across America, and the continuing spread of Nipah virus in Southeast Asia.
• Further reading sections at the end of each chapter make it easy find key references
• World maps depicting the current distribution of existing and newly emerging viruses are also incorporated into the text
• A companion website features illustrations for use in class notes and presentations.

Completely revised and updated, the new edition of this groundbreaking text integrates basic virology with pathophysiological conditions to examine the connection between virology and human disease. Most virology textbooks focus on the molecular biology involved without adequate reference to physiology. This text focuses on viruses that infect humans, domestic animals and vertebrates and is based on extensive course notes from James Strauss’ virology class at the California Institute of Technology taught for over 30 years. Expertly depicting in color the molecular structure and replication of each virus, it provides an excellent overview for students and professionals interested in viruses as agents of human disease.

Origin and Evolution of Viruses, 2nd Edition Edited by Esteban Domingo, Colin R. Parrish, and John J. Holland Hardcover - 560 pages Shipped in CLICK HERE Cat.# EL-BVI4 $138.20 BUY Published:  2008   ISBN:  9780123741530

Table of Contents

1. Early Replication: Origin and Evolution
2. Structure and Evolution of Viroids
3. Mutation, Competition and Selection as Measured with Small RNA Molecules
4. Viral Quasispecies: Dynamics, Interactions and Pathogenesis
5. Comparative Studies of RNA Virus Evolution
6. Nucleic Acid Polymerase Fidelity and Viral Population Fitness
7. The complex Interactions of Viruses and the RNAi Machinery: A Driving Force in Viral Evolution
8. The Role of the APOBEC3 Family of Cytidine Deaminases in Innate Immunity, G-to-A Hypermutation, and Evolution of Retroviruses
9. Lethal Mutagenesis
10. Evolution of dsDNA Tailed Phages
11. More about Plant Virus Evolution
12. Mutant clouds and bottleneck events in plant virus evolution
13. Retrovirus Evolution
14. Intra-host dynamics and evolution of HIV Infection
15. The Impact of Rapid Evolution of Hepatitis Viruses
16. Arbovirus Evolution
17. Evolution and Variation of the Parvoviruses
18. Genome Diversity and Evolution of Papillomaviruses
19. Origin and Evolution of Poxviruses
20. Molecular Evolution of the Herpesvirales
21. The widespread evolutional significance of viruses

Bacteriology of Humans: An Ecological Perspective by Michael Wilson Hardcover - 360 pages Shipped in CLICK HERE Cat.# JW-BVI1 $109.10 BUY Published:  2008   ISBN:  9781405161657

Provides a comprehensive, yet accessible, reference book on the human microbiota

• Lavishly illustrated with colour figures, diagrams, tables and maps
• Each chapter provides a list of references to promote further study
• Each chapter contains links to key websites
• Offers an ecological approach that explains why certain organisms are associated with a particular anatomical site

Until recently, the indigenous microbiota of humans has been a relatively neglected area of microbiology with most attention being focused on those microbes that cause disease in humans, rather than on those that co-exist with us in the disease-free state. However, in the past decade research has shown that not only is the indigenous microbiota involved in protecting humans from exogenous pathogens but it is also involved in our development and nutrition. Consequently, interest has grown substantially among health professionals and scientists in analyzing and understanding these microbial (largely bacterial) communities.

This comprehensive, yet accessible text provides an up-to-date guide to the development, composition and distribution of indigenous microbial communities of humans. With the aid of abundant colour figures, diagrams, tables and maps, it establishes links between the physicochemical factors prevailing at an anatomical site and the types of microbes to be found there. The book includes an introduction to the human-microbe symbiosis as well as an in-depth look at the main systems and organs of the human body that have an indigenous microbiota. Each chapter includes a list of references for further study.

This is an excellent and informative reference book that will be useful to anyone with an interest in microbiology, medical microbiology, microbial ecology, infectious diseases, immunology, human biology, medicine, dentistry, nursing, health sciences, biomedical sciences or pharmacy – it should be on the shelf of every major science and medical library.

Table of Contents:

Preface
Abbreviations of genera

1. The human–microbe symbiosis
1.1. Overview of the nature and distribution of the microbial communities inhabiting humans
1.2. Environmental determinants that affect the distribution and composition of microbial communities
1.3. Host characteristics that affect the indigenous microbiota
1.4. Techniques used to characterize the microbial communities inhabiting humans
1.5. The epithelium – site of host–microbe interactions
1.6. Further reading
2. The indigenous microbiota of the skin
2.1. Anatomy and physiology of human skin
2.2. Cutaneous antimicrobial defense systems
2.3. Environmental determinants operating at different skin regions
2.4. The indigenous microbiota of the skin
2.5. Overview of the cutaneous microbiota
2.6. Sources of data used to compile figures
2.7. Further reading
3. The indigenous microbiota of the eye
3.1. Anatomy and physiology of the eye
3.2. Antimicrobial defense systems of the eye
3.3. Environmental determinants on the conjunctival surface
3.4. The indigenous microbiota of the eye
3.5. Overview of the ocular microbiota
3.6. Sources of data used to compile figures
3.7. Further reading
4. The indigenous microbiota of the respiratory tract
4.1. Anatomy and physiology of the respiratory tract
4.2. Antimicrobial defense systems of the respiratory tract
4.3. Environmental determinants within the respiratory tract
4.4. Indigenous microbiota of the respiratory tract
4.5. Overview of the respiratory microbiota
4.6. Sources of data used to compile figures
4.7. Further reading
5. The indigenous microbiota of the urinary system of females
5.1. Anatomy and physiology of the urinary system of females
5.2. Antimicrobial defenses of the female urinary system
5.3. Environmental determinants within the female urethra
5.4. The indigenous microbiota of the female urethra
5.5. Overview of the microbiota of the urinary tract of females
5.6. Sources of data used to compile figures
5.7. Further reading
6. The indigenous microbiota of the reproductive system of females
6.1. Anatomy and physiology of the female reproductive system
6.2. Antimicrobial defense systems of the female reproductive system
6.3. Environmental determinants at different regions of the reproductive system
6.4. The indigenous microbiota of the female reproductive system
6.5. Overview of the microbiota of the female reproductive system
6.6. Sources of data used to compile figures
6.7. Further reading
7. The indigenous microbiota of the urinary and reproductive systems of males
7.1. Anatomy and physiology
7.2. Antimicrobial defenses of the male urinary and reproductive systems
7.3. Environmental determinants within the male urinary and reproductive systems
7.4. The indigenous microbiota of the male urinary and reproductive systems
7.5. Overview of the microbiota of the male urinary and reproductive systems
7.6. Sources of data used to compile figures
7.7. Further reading
8. The indigenous microbiota of the oral cavity
8.1. Anatomy and physiology of the oral cavity
8.2. Antimicrobial defense systems of the oral cavity
8.3. Environmental determinants at the various sites within the oral cavity
8.4. The indigenous microbiota of the oral cavity
8.5. Overview of the oral microbiota
8.6. Sources of data used to compile figures
8.7. Further reading
9. The indigenous microbiota of the gastrointestinal tract
9.1. Anatomy and physiology of the gastrointestinal tract
9.2. Antimicrobial defense systems of the gastrointestinal tract
9.3. Environmental determinants within different regions of the gastrointestinal tract
9.4. The indigenous microbiota of the gastrointestinal tract
9.5. Overview of the indigenous microbiota of the gastrointestinal tract
9.6. Sources of data used to compile figures
9.7. Further reading
10. The future
10.1. Further reading

Index

Viral Therapy of Cancer by K. J. Harrington, Richard G. Vile, and Hardev Pandha Hardcover - 432 pages Shipped in CLICK HERE Cat.# EL-BVI6 $174.55 BUY Published:  2008   ISBN:  9780470019221

This book provides an in-depth analysis of the current status of all the key viruses that are being developed as treatments for cancer. It is the first book to describe the use of viruses as oncolytic agents, killing cells directly, and it bridges the gap between bench research and clinical applications.

Viral Therapy of Cancer reviews all aspects of viral applications in the treatment of cancer, including quality, control and regulatory issues in various countries. Edited by three experts in the field of cancer gene therapy with experience in both laboratory and clinical research, this book is an invaluable resource for both basic scientists and clinicians with an interest in virology and gene therapy.

Table of Contents:

Foreword
Preface

1. Adenoviruses

1.1 Introduction
1.2 Viral structure and lifecycle
1.3 Adenoviral vectors
1.4 Targeting adenoviral vectors
1.5 Clinical applications of adenoviral gene therapy
1.6 Adenoviral vectors for immunotherapy
1.7 Adenoviral vectors for suicide gene therapy
1.8 Adenoviral vectors for gene replacement therapy
1.9 Oncolytic adenoviral therapy
1.10 Adverse outcomes of adenoviral gene therapy
1.11 Summary

References

2. Application of HSV-1 factors to the treatment of cancer

2.1 Introduction
2.2 Basic biology of HSV
2.3 Replication competent or oncolytic vectors
2.4 Replication defective vectors
2.5 Amplicons
2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy
2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy
2.8 Summary and conclusions

References

3. Adeno-associated virus

3.1 Introduction
3.2 Biology and life cycle of AAV
3.3 AAV serotypes
3.4 Production of recombinant AAV
3.5 Gene therapy for cancer treatment
3.6 Anti-oncogenic properties of AAV
3.7 Molecular chemotherapy studies with rAAV
3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy
3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses
3.10 rAAV vectors can be used to initiate immune responses
3.11 Altering AAV tropism for tumour-specific delivery
3.12 Clinical trials involving rAAV.
3.13 Conclusion

Acknowledgements
References

4. Retroviruses

4.1 Introduction
4.2 Structure of retroviral particles
4.3 Retroviral genome
4.4 Retroviral life cycle
4.5 Retroviral vectors
4.6 Safety of retroviral vectors: insertional mutagenesis
4.7 Gene therapy of X-linked SCID
4.8 Retroviral cancer gene therapy
4.9 Immunomodulatory approaches
4.10 Conclusions

References

5. Lentiviral vectors for cancer gene therapy

5.1 Development of lentiviral vectors (LV)
5.2 Targeting of transgene expression
5.3 Host immune responses to LV and their transgene
5.4 Transgenesis
5.5 Haematopoietic stem cell gene transfer
5.6 Cancer treatment by LV
5.7 Approved clinical trials using LV
5.8 Conclusions

References

6. Poxviruses as immunomodulatory cancer therapeutics

6.1 Introduction
6.2 General features of poxvirus structure and biology
6.3 Clinically applicable poxviruses
6.4 Poxviruses as potential cancer therapeutics
6.5 Clinical experience with poxviruses
6.6 Conclusion

References

7. Oncolytic herpes simplex viruses

7.1 Introduction
7.2 Herpes simplex virology
7.3 Properties of HSV relevant to oncolytic virus therapy
7.4 Mutations giving tumour-selective replication
7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG)
7.6 Prodrug activation therapy and oncolytic HSV
7.7 Combination of oncolytic HSV with immunomodulatory gene expression
7.8 Combination of conventional therapies with oncolytic HSV
7.9 Summary

Acknowledgement
References

8. Selective tumour cell cytotoxicity by reoviridae - preclinical evidence and clinical trial results

8.1 Introduction
8.2 Reovirus structure
8.3 Reovirus replication
8.4 Reovirus and human infection
8.5 Oncolytic activitiy
8.6 Mechanism of reovirus-induced cytotoxicity
8.7 Preclinical experience
8.8 Immunogeneicity
8.9 Clinical experience
8.10 Conclusions

References

9. Oncolytic vaccinia

9.1 Introduction
9.2 Biology of vaccinia virus
9.3 Tumour selectivity and antitumour effect
9.4 Improving antitumour effects through bystander effects
9.5 Immune response to vaccinia and vaccinia immune evasion strategies
9.6 Virus-driven antitumour immune response
9.7 Imaging
9.8 Current and potential clinical applications

References

10. Newcastle Disease virus: a promising vector for viral therapy of cancer

10.1 Introduction
10.2 Structure, taxonomy, pathogenicity and oncolytic properties of NDV
10.3 Human application and safety
10.4 Tumour-selective replication of NDV
10.5 Virally based cancer immunotherapy and danger signals
10.6 NDV: a danger signal inducing vector
10.7 The human cancer vaccine ATV-NDV
10.8 Pre-existing antitumour memory T cells from cancer patients and their activation by antitumour vaccination with ATV-NDV
10.9 Clinical trials of antitumour vaccination with ATV-NDV
10.10 NDV-specific recombinant bispecific antibodies to augment anti-tumour immune responses
10.11 NDV-binding bispecific fusion proteins to improve cancer specific virus targeting
10.12 Recombinant NDV as a new vector for vaccination and gene therapy
10.13 Conclusion

References

11. Vesicular stomatitis virus

11.1 Introduction
11.2 Vesicular stomatitis virus (VSV): genomic organization and life cycle
11.3 Host range and pathogenesis of VSV infection
11.4 Control of VSV infection by the innate type I interferon response
11.5 cancer cells are insensitive to type I interferon
11.6 VSV preferentially replicates in and lyses tumour cells in vitro
11.7 VSV attenuation: enhanced tumour selectivity and therapeutic index
11.8 Engineered/recombinant VSV
11.9 VSV effectively eradicates tumours in vivo
11.10 VSV and the host immune response
11.11 Host immunity vs. therapeutic efficacy
11.12 VSV is a potent vaccine
11.13 Innate sensing of VSV and the antitumour response
11.14 So what is a good oncolytic virus?
11.15 Future challenges for VSV

References

12. Measles as an oncolytic virus

12.1 Introduction
12.2 Measles virus and the consequences of natural infection
12.3 MV vaccine
12.4 MV genetics and engineering
12.5 MV receptors
12.6 Animal models for the study of MV pathogenesis and oncolysis
12.7 Oncolytic activity of MV
12.8 Mechanism of specificity
12.9 Targeting MV entry
12.10 Enhancing the oncolytic activity of MV
12.11 Interactions with the immune system
12.12 Potential specific toxicities of clinical use of replicating attenuated MV
12.13 Clinical trials
12.14 Conclusions

References

13. Alphaviruses

13.1 Introduction
13.2 RNA viruses as gene expression vectors
13.3 The biology of alphaviruses
13.4 Heterologous gene expression using alphavirus vectors
13.5 Cancer gene therapy strategies using alphavirus vectors
13.6 Alphavirus vector development for gene therapy application
13.7 Conclusions

References

14. Tumour-suppressor gene therapy

14.1 Tumour-suppressor genes
14.2 Use of tumour-suppressing genes for cancer therapy
14.3 Clinical trials of p53 gene replacement
14.4 Tumour-suppressor gene therapy in multimodality anticancer treatment
14.5 Future prospects

Acknowledgements
References

15. RNA interference and dominant negative approaches

15.1 Introduction
15.2 Oligonucleotide agents
15.3 Mechanism of RNAi
15.4 RNAi and antisense compared
15.5 siRNA design
15.6 Off-target effects
15.7 Induction of innate immunity
15.8 Methods of delivery
15.9 Antisense
15.10 Dominant negative approaches
15.11 Research applications of siRNA
15.12 Therapeutic applications of siRNA

References

16. Gene-directed enzyme prodrug therapy

16.1 Introduction
16.2 Enzyme-prodrug systems for GDEPT
16.3 Gene delivery vectors for GDEPT
16.4 Conclusions

References

17. Immunomodulatory gene therapy

17.1 Introduction
17.2 Immunotherapy strategies using viral vectors
17.3 Viruses used as viral vectors in cancer immunotherapy
17.4 Clinical trials against specific TAA
17.5 Conclusions and future prospects

References

18. Antiangiogenic gene delivery

18.1 Angiogenesis: role in tumour development and metastasis
18.2 Targeting tumour vasculature as an approach for cancer treatment
18.3 Viral vectors to deliver antiangiogenic gene products
18.4 Viral targeting
18.5 Concluding remarks

References

19. Radiosensitization in viral gene therapy

19.1 Introduction
19.2 Adenovirus
19.3 Adeno-associated viruses
19.4 Herpes simplex viruses
19.5 Enhancing the effect of radiation by delivering tumour suppressor genes
19.5 Virus-directed enzyme prodrug therapy
19.6 Conclusion

References

20. Radioisotope delivery

20.1 Introduction
20.2 History of iodine therapy
20.3 Genetic therapy
20.4 Conclusion

References

21. Radioprotective gene therapy: current status and future goals

21.1 Introduction
21.2 Organ-specific radiation protection: oral cavity/oropharynx
21.3 A potential beneficial added observation of antitumour effect of radiation protection using MnSOD-PL
21.4 HA-MnSOD effects on reducing the repopulation (cytoprotective response) induced by irradiation in tumours and the role of EGFR-TKI
21.5 MnSOD-PL treatment to ameliorate the dose limiting oesophageal toxicity of irradiation
21.6 MnSOD-PL treatment reduces pulmonary irradiation damage
21.7 MnSOD-PL systemic administration for radiation protection from TBI
21.8 Summary and future directions

References

22. Chemoprotective gene delivery

22.1 Introduction
22.2 The promise of chemoselection strategies
22.4 The limitations of chemoselection strategies
22.5 Which expression level of chemoprotective genes is appropriate?
22.6 Vector design to achieve optimal expression levels
22.7 Exploring side effects of continued transgene expression and insufficient chemoprotection
22.8 The future: inducible expression of drug resistance genes

Acknowledgements
References

Novartis Foundation Symposium 290 - Novel and Re-emerging Respiratory Viral Diseases by Novartis Hardcover - 174 pages Shipped in CLICK HERE Cat.# EL-BVI8 $187.30 BUY Published:  2008   ISBN:  9780470065389

In the past two decades, many ‘novel’ viral diseases have struck the world. The latest is avian influenza, which has triggered major epidemiological and surveillance studies worldwide, as well as research into the molecular and physiological characteristics of the virus responsible, H5N1. Previously, a novel coronavirus was identified as the aetiological agent oft he severe acute respiratory syndrome (SARS), a new respiratory viral disease that emerged at the end of 2002 and caused profound disturbances in over 30 countries in 2003. Although this epidemic has been controlled by isolation, much about the virus remains unknown, particularly its origins and potential reservoir(s).

This book critically evaluates the scientific evidence on these viruses, including molecular biology, diagnostics, animal models of viral infection, plus the development of vaccines and anti-viral agents. Virologists from different countries summarize the latest advances in epidemiology, virus identification and public health measures for protection and prevention. Representatives from Canada, China, Hong Kong, Taiwan and Singapore, which had the most cases of infection and the most severe social and economic disturbances, provide critical reviews of problems and solutions encountered during the SARS epidemic. The book also evaluates what was learned from previous flu outbreaks. Representatives from South-East Asian countries review recent bird-to-human avian influenza virus transmissions in their countries and share their experiences in the implementation of effective disease surveillance and control strategies.

Filoviridae: The Marburgviruses and Ebolaviruses by J.H Kuhn, and C. H. Calisher Hardcover - 340 pages Shipped in CLICK HERE Cat.# DA-BVI1 $369.95 BUY Published:  2008   ISBN:  9783211206706

The marburgviruses and ebolaviruses are among the most hazardous pathogens known to mankind. Since these agents are highly virulent, research progress has been rather slow in comparison to other viruses. After it was revealed that the former Soviet Union has evaluated filoviruses for biological weapons development interest in defenses against them has been reawakened. This book provides the most extensive bibliography review of filovirus research publication to date with special emphasis on foreign literature that has never been summarized. Every aspect of filovirus research, including their history, epidemiology, clinical picture, pathology, molecular biology, and political aspects are reviewed in detail.

Contents:

Summary
Preface
Introduction

Definition of Viral Hemorrhagic Fevers
Taxonomy and Evolution of Filoviruses
Biosafety Considerations
Biological Weapons and Biosecurity Concerns
History and Epidemiology
Geographic Distributions/Serosurveys
Clinical Picture
Pathology
Isolation and Cultivation
Ultrastructure and Morphogenesis
Molecular Biology of Filoviruses and Pathogenesis of Filovirus Infections
Prevention and Outbreak Control
Laboratory Diagnosis
Treatment

Appendix
Acknowledgements
References
Additional References

Group B Coxsackieviruses by S. Tracy, M. S. Oberste, and K. M. Drescher Hardcover - 340 pages Shipped in CLICK HERE Cat.# DA-BVI2 $234.50 BUY Published:  2008   ISBN:  9783540755456

Our knowledge of the group B coxsackieviruses has progressed dramatically in the past 60 years. Some of the most recent advances include the identification of the coxsackievirus-adenovirus receptor, the dissection of genetic elements linked to virulence/attenuation, examination of the impact of recombination in virus evolution and diversity, and analysis of the role of viral proteins in regulating host cell macromolecule synthesis and trafficking. The First Edition of this work, published in 1997, described the molecular biology of coxsackie B viruses, as well as clinical, epidemiological, and immunological aspects of group B coxsackievirus disease. Much has been accomplished in the past ten years, including determination of the crystal structure of a virus-receptor complex, significant advances in understanding the molecular details of virus-host interaction within the cell, and deeper insights into the systemic effects of virus infection and the host response.

This Second Edition summarizes the current state of knowledge in group B coxsackievirus genomics and replication, receptor structure and function, host cell interactions, the host immune response and immunopathology, viral virulence and pathogenesis, and the role of this important group of viruses in acute and chronic disease in humans.

Viruses and Apoptosis by Alonso Covadonga Softcover - 340 pages Shipped in CLICK HERE Cat.# DA-BVI3 $114.50 BUY Published:  2008   ISBN:  9783540742630

The interactions between viruses and the cells they infect include the virus control of cellular functions to their advantage. The cell counteracts with a defensive immune system and stress responses. Both sides of this struggle include modifications in the cell death program that will be crucial for the infection outcome. In this book, molecular pathways regulated by viral genes and their role in the pathogenesis of infection are analysed in different viral models. It also includes a didactic update of known signaling pathways in apoptosis and their role in normal and infected cells. Special emphasis was given to molecu